These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 28352421)
41. Does starting allopurinol prolong acute treated gout? A randomized clinical trial. Hill EM; Sky K; Sit M; Collamer A; Higgs J J Clin Rheumatol; 2015 Apr; 21(3):120-5. PubMed ID: 25807090 [TBL] [Abstract][Full Text] [Related]
42. [Analysis of serum lipids levels and the establishment of reference intervals for serum lipids in middle and late pregnancy]. Ying C; Yue C; Zhang C; Li X Zhonghua Fu Chan Ke Za Zhi; 2015 Dec; 50(12):926-30. PubMed ID: 26887877 [TBL] [Abstract][Full Text] [Related]
43. Pharmacotherapy for hyperuricemia in hypertensive patients. Gois PH; Souza ER Cochrane Database Syst Rev; 2013 Jan; (1):CD008652. PubMed ID: 23440832 [TBL] [Abstract][Full Text] [Related]
44. The lipid profile in obese asthmatic children compared to non-obese asthmatic children. Fang LJ; Huang CS; Liu YC; Su YM; Wan KS Allergol Immunopathol (Madr); 2016; 44(4):346-50. PubMed ID: 27112546 [TBL] [Abstract][Full Text] [Related]
45. Aged garlic extract supplementation modifies inflammation and immunity of adults with obesity: A randomized, double-blind, placebo-controlled clinical trial. Xu C; Mathews AE; Rodrigues C; Eudy BJ; Rowe CA; O'Donoughue A; Percival SS Clin Nutr ESPEN; 2018 Apr; 24():148-155. PubMed ID: 29576354 [TBL] [Abstract][Full Text] [Related]
46. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis. Navarro JF; Mora C; Muros M; García-Idoate G Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852 [TBL] [Abstract][Full Text] [Related]
48. LDL-C/apoB and HDL-C/apoA-1 ratios predict incident chronic kidney disease in a large apparently healthy cohort. Bae JC; Han JM; Kwon S; Jee JH; Yu TY; Lee MK; Kim JH Atherosclerosis; 2016 Aug; 251():170-176. PubMed ID: 27341533 [TBL] [Abstract][Full Text] [Related]
49. Statins for treatment of dyslipidemia in chronic kidney disease. Shurraw S; Tonelli M Perit Dial Int; 2006; 26(5):523-39. PubMed ID: 16973506 [TBL] [Abstract][Full Text] [Related]
50. The impact of serum uric acid reduction on renal function and blood pressure in chronic kidney disease patients with hyperuricemia. Tsuji T; Ohishi K; Takeda A; Goto D; Sato T; Ohashi N; Fujigaki Y; Kato A; Yasuda H Clin Exp Nephrol; 2018 Dec; 22(6):1300-1308. PubMed ID: 29700702 [TBL] [Abstract][Full Text] [Related]
51. Benefits of Allopurinol Treatment on Blood Pressure and Renal Function in Patients with Early Stage of Chronic Kidney Disease. Satirapoj B; Wirajit O; Burata A; Supasyndh O; Ruangkanchanasetr P J Med Assoc Thai; 2015 Dec; 98(12):1155-61. PubMed ID: 27004299 [TBL] [Abstract][Full Text] [Related]
52. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913 [TBL] [Abstract][Full Text] [Related]
53. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. Elam MB; Hunninghake DB; Davis KB; Garg R; Johnson C; Egan D; Kostis JB; Sheps DS; Brinton EA JAMA; 2000 Sep; 284(10):1263-70. PubMed ID: 10979113 [TBL] [Abstract][Full Text] [Related]
54. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468 [TBL] [Abstract][Full Text] [Related]
56. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546 [TBL] [Abstract][Full Text] [Related]
57. Metabolic and antihypertensive effects of nebivolol and atenolol in normometabolic patients with mild-to-moderate hypertension. Pesant Y; Marc-Aurèle J; Bielmann P; Alaupovic P; Cartier P; Bichet D; Thibault G; Lupien PJ Am J Ther; 1999 May; 6(3):137-47. PubMed ID: 10423656 [TBL] [Abstract][Full Text] [Related]
58. Lipid effects of an intrauterine levonorgestrel device or oral vs. vaginal natural progesterone in post-menopausal women treated with percutaneous estradiol. Suvanto-Luukkonen E; Sundström H; Penttinen J; Kauppila A Arch Gynecol Obstet; 1998; 261(4):201-8. PubMed ID: 9789651 [TBL] [Abstract][Full Text] [Related]
59. Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy. Lussier-Cacan S; Xhignesse M; Desmarais JL; Davignon J; Kafrissen ME; Chapdelaine A Metabolism; 1991 Aug; 40(8):849-54. PubMed ID: 1907348 [TBL] [Abstract][Full Text] [Related]